Home/Filings/4/A/0001209191-21-047507
4/A//SEC Filing

Brigido Stephen 4/A

Accession 0001209191-21-047507

CIK 0001752828other

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 9:07 PM ET

Size

11.7 KB

Accession

0001209191-21-047507

Insider Transaction Report

Form 4/AAmended
Period: 2021-07-16
Brigido Stephen
Pres., Functional Regeneration
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-07-16+20,37920,379 total
    Exercise: $3.70Exp: 2031-07-16Class A Common Stock (20,379 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-07-16+153,718153,718 total
    Exercise: $3.70Exp: 2031-07-16Class A Common Stock (153,718 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-07-16+76,85976,859 total
    Exercise: $10.21Exp: 2031-07-16Class A Common Stock (76,859 underlying)
Footnotes (4)
  • [F1]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, December 15, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
  • [F2]Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."
  • [F3]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, August 30, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
  • [F4]This option is fully vested and exercisable.

Issuer

Celularity Inc

CIK 0001752828

Entity typeother

Related Parties

1
  • filerCIK 0001869791

Filing Metadata

Form type
4/A
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 9:07 PM ET
Size
11.7 KB